Page 4 - Serum Institute Of India

Serum Institute to provide 20 mn Covishield doses to govt free of cost

The Serum Institute of India (SII) has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said on Wednesday. According to an official source, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute, has written to the Health Ministry offering the doses worth Rs 410 crore free of cost. It is learnt that Singh has sought to know from the ministry how the delivery can be made. SII has so far provided more than 170 crore doses of Covishield to the government for the national immunisation programme. Amid a spike in COVID-19 cases in some countries, including China and South Korea, the government has sounded an alert and asked states and Union territories to prepare for any eventuality. India has stepped its surveillance and genome sequencing of Covid positive samples. With only 27 per cent of the eligible adult population having taken the precaution do

Serum Institute seeks market authorisation of its vaccine as booster dose

The Serum Institute of India (SII) has sought the drug regulator's approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for the heterologous booster dose of Covovax to the drugs controller general of India (DCGI) on October 17. It has been learnt that the DCGI's office had raised a few queries, after which Singh submitted a reply, mentioning about the current emerging situation caused by a new coronavirus variant. Covovax was approved by the DCGI for a restricted emergency use in children aged seven to 11 years in June. The DCGI had approved Covovax for a restricted use in emergency situations in adults on December 28, 2021 and for those in the 12-17 age group, subject to certain conditions, on March 9. Cov

Rising Covid cases in China a concern but India need not panic: SII CEO

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent. Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of positive samples to keep track of newer variants, if any, amid a spurt in cases in the US and China. "The news of rising COVID cases coming out of China is concerning, we need not panic given our excellent vaccination coverage and track record. We must continue to trust and follow the guidelines set by the Government of India and @MoHFW_INDIA," Poonawalla tweeted. During the COVID-19 pandemic, the Pune-based SII had collaborated with Oxford University and pharmaceutical company Astra Zeneca for making the Covishield vaccine. In October, Pooanwalla said the SII stopped producing the vaccine in December 2021. Of the total stock available at that

Serum Institute, Byju's top Burgundy-Hurun unlisted companies list

The Pune-based vaccine producer's value has increased 20 per cent to Rs 2.2 trillion in the past one year

Covishield production stopped in Dec 2021, says Serum Institute's CEO

CEO Adar Poonawalla said Serum Institute of India stopped producing Covishield vaccine from December 2021 and of the total stock available at that time, about 100 million doses had already expired

HPV vaccine prodn delayed due to Covid, to start supply in early 2023: SII

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on COVID, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said. Exports will have to wait till 2024, its chief executive Adar Poonawalla told reporters here on Thursday evening, adding that the company has to build a scale of manufacturing to over 150 million for that. HPV vaccines prevent certain kinds of cervical cancer. SII is the world's largest vaccine manufacturer which rushed with the production of multiple COVID vaccines at its facilities located here once the shot was approved for use. "The HPV facility was used by the COVID vaccines during the pandemic. That's why we had to delay the larger launch to next year," Poonawalla said, speaking on the sidelines of an event. "We will be making a very small quantity and launching with the Indian government in the first quarter of next year. Followed by a capacity for 70

Developing nations' vaccine manufacturers bat for pandemic treaty

It's time to focus on routine immunisation: Mandaviya

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers Network (DCVMN), he said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic. "Since December 2021, we stopped the production (of Covishield). We had a stock of a few hundred million doses at that time and of that, 100 million doses have already expired," said Poonawalla when asked about the update on the Covishield vaccine. He said the SII's vaccines are allowed to be mixed. "Now, Covovax should be allowed in two weeks. So I think they will and should probably have the policy to mix boosters. If WHO allowed it, then .

SII's Poonawalla makes clarion call for global certification of vaccines

Multilateral organisations like the UN and the WTO should take it upon themselves to harmonise the certification of vaccines especially ahead of another pandemic as witnessed one induced by the COVID-19 virus that has badly hit the global economies, CEO of Serum Institute of India, Adar Poonawalla has said. Making this clarion call at the Forbes Global CEO Conference in Singapore on Monday, Poonawalla said I'm proposing it (such a certification treaty)." "Multilateral organisations such as the United Nations and the World Trade Organisation should take it upon themselves to harmonise the certification of vaccines," he told PTI on the sideline of the conference, adding that "the world needs it if we want to be prepared in the future". Responding to a question on lessons learned from COVID-19, Poonawalla was quick to acknowledge the challenges of having such a proposal given the concerns of world leaders. I will keep advocating for it (the proposal), though getting the world leaders

Top Headlines: Gyanvapi verdict today, Russia's discounted oil, and more

In a bid to counter the growing clamour among the G7 nations to enforce a price cap on Russian oil, Moscow told New Delhi it is willing to provide petroleum at even lower rates than before to India

Scamsters posing as Adar Poonawala dupe Serum Institute of over Rs 1 crore

An FIR was launched against some unidentified persons for cheating the Serum Institute of India for more than Rs 1 crore, said the officials

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Covishield vax death: Bombay HC issues notices to govt, Bill Gates, SII

The petitioner is Dilip Lunawat, who has contended that his daughter Snehal Lunawat, 33, who was also a Senior Lecturer at the SMBT Dental College in Nashik, was compelled to take the vaccine

India-made cervical cancer vaccine Ceravac to cost Rs 200-400 per dose

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

South Africa's Aspen, India's Serum Institute sign vaccines deal for Africa

South Africa's Aspen Pharmacare has signed a deal with the Serum Institute of India to manufacture and sell four Aspen-branded vaccines for Africa

Serum Institute CEO calls on PM Modi, praises his 'remarkable leadership'

Serum Institute of India CEO Adar Poonawalla on Tuesday called on Prime Minister Narendra Modi and congratulated him for his leadership in the fight against the COVID-19 pandemic. In a tweet, Poonawalla said he met Modi on Tuesday. "Delighted to have met PM, Shri @narendramodi Ji. Congratulated him for his remarkable leadership and success in the fight against COVID-19. As an entrepreneur, I find his commitment to reforms, social welfare, and vision for Aatmanirbhar Bharat very assuring," he tweeted. Pune-based Serum Institute of India is the world's largest company in terms of COVID-19 vaccine production.

Serum Institute, other firms eye tie-ups to develop monkeypox vaccine

Indian Immunologicals, and Haffkine Research Institute also in the fray

At least 8 Indian companies working to develop monkeypox vaccine: Report

Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E

SII may use Oxford Biomedica's plant to make malaria, flu vaccines

SII is building a future pandemic facility, which will have an annual capacity of 2 bn doses

India likely to get Omicron-specific vaccine by year-end, says SII chief

SII is working with Novavax to bring the Omicron-specific vaccine, as the nation continues to record a surge in the number of Covid-19 cases